Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer

Official Title

Phase II Randomized Double Blind Placebo Controlled Trial of Combination of Pimasertib With SAR245409 or of Pimasertib With SAR245409 Placebo in Subjects With Previously Treated Unresectable Low Grade Ovarian Cancer

Summary:

This is a double blind, randomized, placebo-controlled, 2-arm, Phase 2 trial investigating the efficacy and safety of combination therapy of pimasertib plus SAR245409 and pimasertib placebo administered once per day compared to pimasertib administered twice per day plus SAR245409 placebo administered once per day in subjects with previously treated unresectable low-grade ovarian cancer.

Trial Description

Primary Outcome:

  • Objective Tumour Response
Secondary Outcome:
  • Progression-Free Survival
  • Percentage of Subjects With Disease Control
  • Overall Survival
  • Health Related Quality of Life (HrQoL) Assessed Using European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ-C30)
  • Health Related Quality of Life (HrQoL) Assessed Using European Organization for Research and Treatment of Cancer (EORTC) Ovarian-Specific Module Quality of Life Questionnaire Ovarian Cancer Module (QLQ-OV28)
  • Number of Subjects With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), TEAEs Leading to Discontinuation of Treatment and Death
  • Maximum Plasma Concentration (Cmax) After Dose of Pimasertib and SAR245409
  • Area Under the Curve (AUC) After Dose of Pimasertib and SAR245409
  • Molecular Alterations in MAPK and/or PI3K Signaling Pathway Components/Modulators in Tumour Tissue and Blood

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society